Microsatellite Instability (MSI)

**Microsatellite Instability (MSI)** is a molecular phenomenon characterized by mutations or instability in short repetitive DNA sequences called **microsatellites**. These microsatellites are prone to errors during DNA replication, and MSI occurs due to defects in the **DNA mismatch repair (MMR) system**, which normally corrects such errors. MSI is a hallmark of certain cancers and has important diagnostic, prognostic, and therapeutic implications.

---

### **Key Features of Microsatellite Instability (MSI)**

#### **Definition**

• **Microsatellites**: Short, repetitive DNA sequences consisting of mono-, di-, tri-, or tetranucleotide repeats, scattered throughout the genome.
• **Microsatellite Instability (MSI)**: A condition where these microsatellite regions exhibit mutations or instability due to defective MMR, leading to insertion or deletion errors during DNA replication.

---

### **Mechanism of MSI**

#### **Normal DNA Mismatch Repair (MMR) System**:

• The MMR system is responsible for correcting replication errors, such as base mismatches and insertion-deletion loops.
• Key MMR genes include:
• **MLH1** (MutL homolog 1)
• **MSH2** (MutS homolog 2)
• **MSH6** (MutS homolog 6)
• **PMS2** (Post-Meiotic Segregation 2)

#### **Defective MMR**:

• Loss of function in one or more MMR genes prevents the correction of replication errors.
• This leads to instability in microsatellite regions, resulting in mutations that can affect oncogenes and tumor suppressor genes, contributing to cancer development.

---

### **Causes of MSI**

#### **Hereditary Causes**:

1. **Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer, HNPCC)**:

• Caused by germline mutations in MMR genes (e.g., MLH1, MSH2, MSH6, PMS2).
• Autosomal dominant inheritance.
• Associated with colorectal, endometrial, ovarian, and gastric cancers.

#### **Sporadic Causes**:

1. **Epigenetic Silencing**:

• Hypermethylation of the **MLH1 promoter**, leading to loss of MLH1 expression.
• Common in sporadic colorectal and gastric cancers.

2. **Somatic Mutations**:

• Acquired mutations in MMR genes.

---

### **Clinical Features of MSI**

#### **Cancers Associated with MSI**:

1. **Colorectal Cancer**:

• MSI is present in ~15% of sporadic colorectal cancers and >90% of Lynch syndrome-associated colorectal cancers.
• Typically occurs in the **proximal colon**.

2. **Gastric Cancer**:

• MSI is found in ~10–50% of sporadic gastric cancers.

3. **Endometrial Cancer**:

• MSI is identified in ~30% of endometrial cancers.

4. **Other Cancers**:

• Ovarian, pancreatic, hepatobiliary, and small intestinal cancers.

#### **Prognostic Features**:

• **MSI-High (MSI-H)** tumors:
• Associated with better prognosis in colorectal cancer (stage-adjusted survival advantage).
• Reduced likelihood of lymph node metastasis.
• Increased tumor mutational burden (TMB), leading to enhanced immunogenicity.

---

### **Diagnostic Approach for MSI**

#### **Indications for MSI Testing**:

1. **Suspected Lynch Syndrome**:

• Early-onset colorectal or endometrial cancer.
• Family history of Lynch-associated cancers.

2. **Sporadic Colorectal or Gastric Cancer**:

• Routine testing in cancer management.

#### **Methods of MSI Detection**:

1. **Immunohistochemistry (IHC)**:

• Detects expression of MMR proteins (MLH1, MSH2, MSH6, PMS2).
• Loss of protein expression indicates defective MMR.

2. **Polymerase Chain Reaction (PCR)**:

• Identifies instability in predefined microsatellite markers (e.g., BAT25, BAT26).
• Tumors are classified as:
• **MSI-High (MSI-H)**: Instability in ≥30% of markers.
• **MSI-Low (MSI-L)**: Instability in <30% of markers.
• **Microsatellite Stable (MSS)**: No instability.

3. **Next-Generation Sequencing (NGS)**:

• Detects MSI and tumor mutational burden (TMB).

4. **MLH1 Promoter Methylation Testing**:

• Used to distinguish epigenetic silencing of MLH1 in sporadic cancers from Lynch syndrome.

---

### **Therapeutic Implications of MSI**

#### **Immune Checkpoint Inhibitors**:

• MSI-H tumors have high TMB, resulting in increased neoantigen expression and enhanced tumor immunogenicity.
• **Immune checkpoint inhibitors** targeting **PD-1/PD-L1** or **CTLA-4** are highly effective in MSI-H tumors.
• Example: **Pembrolizumab** (anti-PD-1 therapy) is approved for MSI-H metastatic cancers.

#### **Chemotherapy**:

• MSI-H colorectal cancers show **poor response to 5-fluorouracil (5-FU)**-based chemotherapy.
• Alternative chemotherapy regimens may be required.

#### **Targeted Therapy**:

• Research is ongoing to develop MSI-specific molecular therapies.

---

### **Prognosis of MSI-H Tumors**

| **Tumor Type** | **MSI-H Tumors** | **MSS Tumors** |

|---------------------------|---------------------------------------------------|-------------------------------------------------|

| **Prognosis** | Better overall prognosis due to immune activation | Worse prognosis in many cancers |

| **Response to Immunotherapy** | Excellent response to immune checkpoint inhibitors | Poor response |

| **Chemotherapy Sensitivity** | Reduced sensitivity to 5-FU-based chemotherapy | Standard chemotherapy response |

---

### **Summary Table**

| **Feature** | **Microsatellite Instability (MSI)** |

|----------------------------|-------------------------------------------------|

| **Definition** | Instability in short tandem DNA repeats due to defective MMR |

| **Causes** | Lynch syndrome (hereditary), MLH1 promoter methylation (sporadic) |

| **Associated Cancers** | Colorectal, gastric, endometrial, ovarian |

| **Diagnostic Methods** | IHC, PCR, NGS, MLH1 promoter methylation testing |

| **Therapeutic Implications** | Immune checkpoint inhibitors (e.g., pembrolizumab) |

| **Prognosis** | Better prognosis in MSI-H tumors |

---

### **Clinical Pearls**

1. **MSI Testing**:

• Essential in colorectal and endometrial cancers to identify Lynch syndrome and guide therapy decisions.

2. **Immunotherapy**:

• MSI-H tumors respond exceptionally well to immune checkpoint inhibitors, making MSI status crucial for treatment planning.

3. **Prognostic Value**:

• MSI-H tumors generally have a better prognosis due to their immunogenicity.

---

### **Takeaway Points**

• **Microsatellite instability (MSI)** results from defective DNA mismatch repair and is a hallmark of Lynch syndrome and sporadic cancers.
• MSI testing is critical for diagnosis, prognosis, and therapeutic decision-making, particularly in colorectal and gastric cancers.
• **MSI-H tumors** benefit significantly from immune checkpoint inhibitors, revolutionizing treatment in advanced cancers.